EcoR1 Capital LLC Has $15.73 Million Stake in Voyager Therapeutics, Inc. $VYGR

EcoR1 Capital LLC increased its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 497.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,002,847 shares of the company’s stock after buying an additional 3,332,544 shares during the period. Voyager Therapeutics accounts for 0.7% of EcoR1 Capital LLC’s holdings, making the stock its 20th largest position. EcoR1 Capital LLC owned 7.20% of Voyager Therapeutics worth $15,731,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wexford Capital LP bought a new position in Voyager Therapeutics in the third quarter valued at approximately $42,000. ProShare Advisors LLC bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $44,000. CIBC Asset Management Inc bought a new position in Voyager Therapeutics in the fourth quarter valued at approximately $45,000. Coldstream Capital Management Inc. bought a new position in Voyager Therapeutics in the third quarter valued at approximately $55,000. Finally, EHP Funds Inc. bought a new position in Voyager Therapeutics in the third quarter valued at approximately $58,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Stock Up 2.5%

Shares of Voyager Therapeutics stock opened at $3.62 on Thursday. Voyager Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $5.55. The stock has a market cap of $218.72 million, a price-to-earnings ratio of -1.84 and a beta of 1.25. The company’s fifty day moving average is $3.81 and its 200 day moving average is $3.93.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. As a group, equities analysts anticipate that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VYGR has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Truist Financial raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. Finally, HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 11,511 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total transaction of $44,547.57. Following the transaction, the chief executive officer owned 472,549 shares in the company, valued at approximately $1,828,764.63. This represents a 2.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 12.70% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.